Kymera Therapeutics at Morgan Stanley conference: oral degrader push

On 15 September 2026, Kymera Therapeutics (KYMR) addressed the Morgan Stanley 24th Annual Global Healthcare Conference to highlight the potential of targeted protein degradation in the market for immune-inflammatory drugs. The company showcased promising early clinical data, rapid trial enrollment, and a robust pipeline, while also emphasizing the need to validate these results in larger studies and various indications.

The main focus of Kymera's efforts is its oral STAT6 degrader, KT-621, which is currently being developed to treat atopic dermatitis and has the potential to expand into other conditions such as asthma, chronic obstructive pulmonary disease, eosinophilic esophagitis, chronic rhinosinusitis with nasal polyps, and chronic spontaneous urticaria.

Another promising program is KT-579, an oral IRF5 degrader for lupus and other autoimmune diseases, which is being developed in partnership with Sanofi. A second-generation IRAK4 degrader, KT-485, is also in the works with Sanofi.

Kymera has shifted its primary focus to immunology, with KT-621 as the lead wholly owned program. The company believes that KT-621 could significantly expand the atopic dermatitis market beyond the current 5% of the 8 million U.S. moderate to severe patient population treated by advanced systemic therapy. Encouraging early data from the Phase I-B BROADEN1 study showed near-complete STAT6 degradation, favorable biomarker movement, and a pristine safety profile.

Enrollment in the Phase IIb BROADEN2 study for KT-621 has progressed faster than anticipated, with hundreds of patients seeking entry. Kymera expects to receive key readouts for KT-579 and KT-621 in late 2024, with asthma data from the BREADTH study expected in 2027. The company's CEO, Nello Cristianini, emphasized that Kymera was founded nearly a decade ago to pursue targeted protein degradation, a method that can reach proteins that traditional drug classes cannot easily address.

So far, only 20% to 25% of the proteome has been targeted, and the company sees targeted protein degradation as a way to expand the range of targets it can pursue.

Over the past six years, Kymera has narrowed its focus almost entirely to immunology, a decision that reflects the company's belief in the best risk-reward profile for patients with immune-inflammatory diseases. This strategic focus has been rewarded by investors, with the stock surging 142% over the past year to $114.63, giving Kymera a market capitalization of $9.5 billion.

However, InvestingPro analysis suggests that the shares may be overvalued relative to fair value estimates, indicating that the market may be pricing in significant optimism about the pipeline's commercial potential.